ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Gastroenterology · United European Gastroenterol J · 2026-05-01

Post hoc analysis of 2 phase 3 trials in moderately to severely active ulcerative colitis (n=1162): week-12 clinical response with mirikizumab was 69.8% with no prior advanced therapy failure, 63.9% after 1, 45.3% after 2 or more and 41.9% in difficult-to-treat disease.

Secondary analysisn = 1,162
Hart et al. Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.